{
    "organizations": [],
    "uuid": "078a78d87891b31a39c1e10c4b13b3b806d201cc",
    "author": "Peter Landers",
    "url": "https://www.wsj.com/articles/biogen-ceo-calls-share-slump-an-overreaction-to-alzheimers-trial-1519118911",
    "ord_in_thread": 0,
    "title": "Biogen CEO Calls Share Slump an Overreaction to Alzheimer’s Trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "TOKYO—Biogen Inc.’s chief executive said investors overreacted when they pushed down the company’s share price nearly 7% on news that it was adding patients to trials of an Alzheimer’s disease drug.\n“It’s very common that we have to increase the sample size, and we don’t take that as a sign that influences whatsoever the outcome of the study,” said Michel Vounatsos, head of the Cambridge, Mass., drugmaker, in an interview on a visit to Japan, where Biogen is trying to expand its presence.\n... To Read the Full Story Subscribe Sign In",
    "published": "2018-02-20T12:28:00.000+02:00",
    "crawled": "2018-02-21T04:00:29.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "chief",
        "executive",
        "said",
        "investor",
        "overreacted",
        "pushed",
        "company",
        "share",
        "price",
        "nearly",
        "news",
        "adding",
        "patient",
        "trial",
        "alzheimer",
        "disease",
        "drug",
        "common",
        "increase",
        "sample",
        "size",
        "take",
        "sign",
        "influence",
        "whatsoever",
        "outcome",
        "study",
        "said",
        "michel",
        "vounatsos",
        "head",
        "cambridge",
        "drugmaker",
        "interview",
        "visit",
        "japan",
        "biogen",
        "trying",
        "expand",
        "presence",
        "read",
        "full",
        "story",
        "subscribe",
        "sign"
    ]
}